Jan 8 (Reuters) - Beigene Ltd:
* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION
* BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD.
* BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE
* BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS
* BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATIâ€˜S SITRAVATINIB IN ASIA Source text for Eikon: Further company coverage:
 